Results 41 to 50 of about 49,427 (236)

Mutations of c-Cbl in myeloid malignancies [PDF]

, 2006
Next generation sequencing has shown the frequent occurrence of point mutations in the ubiquitin E3 ligase c-Cbl in myeloid malignancies. Mouse models revealed a causal contribution of c-Cbl for the onset of such neoplasms.
Bloomfield, Weissman, Weissman, Weissman, Weissman, Weissman, Zon, Sigvardsson, Cancer Genome, Baltimore, Birnbaum, Huibregtse, Weissman, Weissman, Dikic, Lipkowitz, Huang, Inagaki, Lipkowitz, Liu, Yarden, Chen, Swaminathan, Samelson, Schmitz, Oliver, Spiekermann, Maciejewski, Chase, Lipkowitz, Whitman, Maciejewski, Bock, Masuda, Birnbaum, Kawamata, Band, Reiter, Bowtell, Band, Langdon, Chaffanet, Rodriguez, Aplan, Voet, Shih, Haferlach, Hirai, Corey, Corey, Hattori, Lowell, Shimizu, Loh, Barber, Roussel, Flavell, Sieweke, Stanley, Berton, Stanley, Cortes, Penninger, Anderson   +63 more
core   +4 more sources

Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms

Haematologica, 2013
Most DNA methylation studies in classic Philadelphia-negative myeloproliferative neoplasms have been performed on a gene-by-gene basis. Therefore, a more comprehensive methylation profiling is needed to study the implications of this epigenetic marker in
Cristina Pérez, Marien Pascual, José Ignacio Martín-Subero, Beatriz Bellosillo, Victor Segura, Eric Delabesse, Sara Álvarez, María José Larrayoz, José Rifón, Juan Cruz Cigudosa, Carles Besses, María José Calasanz, Nicholas C.P. Cross, Felipe Prósper, Xabier Agirre   +14 more
doaj   +1 more source

Severe Case of Peripheral Leukocytosis Initially Diagnosed as Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, but Possibly Prefibrotic Primary Myelofibrosis [PDF]

, 2014
Leukocytosis is occasionally seen in patients with presumptive but undiagnosed myeloproliferative disorders (MPD). A 74-year-old woman was admitted to our hospital for tarry stools, anemia, and marked peripheral leukocytosis of 1.4×105/μL ...
Hiramatsu, Yasushi, Kasahara, Akinori, Kondo, Eisei, Matsumura, Tadashi, Noguchi, Toshio, Ota, Seisuke, Takada, Saimon, Tanimoto, Mitsune, Umena, Sachio   +8 more
core   +1 more source

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

Frontiers in Hematology
The myeloproliferative neoplasms (MPNs) – polycythemia vera, essential thrombocytosis, and primary myelofibrosis – are chronic blood cancers that originate from hematopoietic stem cells carrying driver mutations which activate cytokine signaling pathways
Joshua W. Bliss, Spencer Krichevsky, Spencer Krichevsky, Joseph Scandura, Ghaith Abu-Zeinah   +4 more
doaj   +1 more source

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients [PDF]

, 2015
Background : Three subtypes of myeloproliferative neoplasms (MPNs): Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) showed overlapping phenotype.
Faradz, S. M. (Sultana), Saktini, F. (Fanti), Santosa, S. (Santosa)   +2 more
core   +3 more sources

Molecular biology of Philadelphia-negative myeloproliferative neoplasms

Revista Brasileira de Hematologia e Hemoterapia, 2012
Myeloproliferative neoplasms are clonal diseases of hematopoietic stem cells characterized by myeloid hyperplasia and increased risk of developing acute myeloid leukemia.
Paulo Vidal Campregher, Fábio Pires de Souza Santos, Guilherme Fleury Perini, Nelson Hamerschlak   +3 more
doaj   +1 more source

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]

, 2019
Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V., Casimiro P., Contrino A. D., Di Piazza F., Perez A., Raso S., Russo A., Santoro M., Siragusa S.   +8 more
core   +1 more source

One thousand patients with essential thrombocythemia: the Florence-CRIMM experience

Blood Cancer Journal
We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18–95), females 65%, JAK2/CALR/MPL-mutated 66%/19%/4%
Giuseppe G. Loscocco, Francesca Gesullo, Giulio Capecchi, Alessandro Atanasio, Chiara Maccari, Francesco Mannelli, Alessandro M. Vannucchi, Paola Guglielmelli   +7 more
doaj   +1 more source

The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]

, 2020
Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M, Fleischman, Angela G, Huynh, Christy, Morse, Sarah J, Nguyen, Hellen, Nguyen, Jenny, Nguyen, Thanh Kim   +6 more
core  

Differential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms [PDF]

, 2010
We evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34 + cells were transplanted intra-femorally.
Cheung, AMS, Fung, TK, Kwong, YL, Leung, AYH, Liang, R   +4 more
core   +1 more source